Genmab equity rallied sharply following encouraging late-stage oncology data, reinforcing its pipeline strength in competitive solid tumor markets.

Shares of Genmab surged following encouraging clinical data from its oncology program, lifting sentiment across the European and U.S. biotechnology sectors.